Anbio Biotechnology is a Cayman-controlled in vitro diagnostics distributor whose public Class A stub has collapsed back toward the listing print after a violent post-IPO spike, and the live debate is whether last year's mix-driven profit is a real franchise or an accrual story sitting under a newly hardened control structure. The operating company designs assays, farms manufacturing to original equipment makers, and sells through distributors in Europe, Asia, and the Americas. Controllers already held nearly all the votes before the May recapitalization. The listed float is a passive claim on a very small revenue base rather than a claim on a scaled diagnostics platform.
Last year the mix-shift away from pandemic tests lifted reported earnings far faster than sales, while cash from operations moved the other way. Two named customer relationships still produced nearly half of annual sales, and two suppliers produced all of the merchandise. Prepayments then ballooned to a multiple of annual cost of sales, which is the mechanical way a thin original-equipment model can book high accounting income without collecting cash. Unused listing proceeds remaining on the year-end cash line make that working-capital absorption harder to dismiss as ordinary growth investment. The income statement and the cash-flow statement are no longer telling the same story.
The May meeting then raised Class B votes from fifty to five hundred per share and authorized a multi-trillion share pool plus reverse-split authority, after which management filed an automatic mixed shelf. The next test is whether cash conversion turns and whether the customer book broadens before that shelf and that authorized pool are used. A twenty-seven-person outsourced platform still has to prove that last year's margin print can become collected cash without diluting the public stub.